Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Volume Increase – Here’s What Happened

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw unusually-strong trading volume on Tuesday . Approximately 2,726,364 shares traded hands during trading, an increase of 138% from the previous session’s volume of 1,146,318 shares.The stock last traded at $11.27 and had previously closed at $11.10.

Analyst Ratings Changes

BAYRY has been the topic of a number of recent research reports. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 24th. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Finally, Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The business’s fifty day moving average price is $12.29 and its 200-day moving average price is $10.29. The stock has a market cap of $45.59 billion, a PE ratio of -10.45 and a beta of 0.69. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.